[Phase I clinical trial of a new myocardial imaging agent, 99mTc-PPN1011].
A new myocardial imaging agent, 99mTc-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane (99mTc-PPN1011) was administered to healthy male volunteers to evaluate its safety and kinetics. No significant drug-related events were observed. After intravenous injection, blood clearance was rapid. Prompt heart uptake (1.8% of the injected dose after 5 minutes) was followed by relatively slow wash-out (1.0% remained after 3 hours). Liver and lung uptake was observed but the clearance was more rapid than in the heart. 4.7-24.0% of the injected 99mTc-PPN1011 was excreted into urine until 4 hours after injection. 99mTc-PPN1011 also seemed to be excreted through hepato-biliary system. Excellent and low-background myocardial images were obtained using either SPECT or planar imaging. We conclude that 99mTc-PPN1011 could be useful for myocardial perfusion imaging.
Kubo
A
A
Department of Radiology, School of Medicine, Keio University.
Nakamura
K
K
Hashimoto
J
J
Sammiya
T
T
Iwanaga
S
S
Hashimoto
S
S
Sasaki
Y
Y
D000328:Adult; D005069:Evaluation Studies as Topic; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D014018:Tissue Distribution
D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; C078700:technetium tc-99m tetrofosmin